Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.57 |
| ▸ | ATG7 | O95352 | 1/20 | 0.57 |
| ▸ | UBA7 | P41226 | 1/20 | 0.57 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.57 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32662675 | 0.89 | ADORA1 (0.60) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32661823 | 0.83 | ADORA1 (0.65) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1798569 | 0.83 | ADORA1 (0.65) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1798642 | 0.82 | UBA6 (0.58) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662224 | 0.82 | ADORA1 (0.74) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1796399 | 0.81 | UBA6 (0.61) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662540 | 0.81 | SLC29A1 (0.64) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662283 | 0.80 | ADORA1 (0.66) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662240 | 0.80 | UBA6 (0.61) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32661927 | 0.80 | LMNA (0.73) | UBA6ATG7UBA7NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2026-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | NAE1, NEDD8, UBA3 | UBA6 153/4885ATG7 884/4885UBA7 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.